← Back to Search

Macrolide Antibiotic

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

Phase 2
Waitlist Available
Led By Brad H Feldman, MD
Research Sponsored by Philadelphia Eye Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2,4 and 6 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 30 Other Conditions

Summary

The purpose of this study is to evaluate the effect of Azasite on patients with corneal surface irregularity (meibomian gland dysfunction).

Eligible Conditions
  • Meibomian Gland Dysfunction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2,4 and 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2,4 and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Astigmatism
Best corrected distance visual acuity
Change in Corneal Irregularity Measurement
+4 more
Other study objectives
Tear film break-up time

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 30 Other Conditions
This treatment demonstrated efficacy for 30 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment eyeExperimental Treatment1 Intervention
Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
Group II: DurasitePlacebo Group1 Intervention
Vehicle of Azasite used as placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Azithromycin
FDA approved

Find a Location

Who is running the clinical trial?

Philadelphia Eye AssociatesLead Sponsor
1 Previous Clinical Trials
51 Total Patients Enrolled
Thomas Jefferson UniversityOTHER
465 Previous Clinical Trials
176,852 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
4,029 Previous Clinical Trials
5,189,621 Total Patients Enrolled
Brad H Feldman, MDPrincipal InvestigatorPhiladelphia Eye Associates
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top